HAVCR2 and acute myeloid leukemia: Notably, the exhaustion marker TIM3 displayed a significantly higher expression in AML‐CTLs than control‐CTLs (FDR < 0.05), whereas no significant difference was detected in the expression of other molecules, including PD‐1 and CTLA‐4 that represent targets of approved drugs used for specific cancer patient groups.